Alejandro Llanos-Cuentas *

Autor invitado por SIIC

Se necesitan nuevas alternativas para el tratamiento de leishmaniasis mucocutánea.

LA AMINOSODINA NO ES EFECTIVA PARA LA LEISHMANIASIS MUCOCUTANEA

La aminosidina parenteral no es efectiva para el tratamiento de la leishmaniasis mucocutánea causada por L. (V.) braziliensis en Perú. La combinación de aminosidina parenteral con un antimonial pentavalente amerita su evaluación debido a que se requieren nuevos medicamentos o combinaciones de medicamentos para el tratamiento de esta enfermedad altamente prevalente, desfigurante y difícil de tratar.

*Alejandro Llanos-Cuentas
describe para SIIC los aspectos relevantes de su trabajo
PARENTERAL AMINOSIDINE IS NOT EFFECTIVE FOR PERUVIAN MUCOCUTANEOUS LEISHMANIASIS
Institución principal de la investigación
*, Lima, Perú, Lima, Perú
Imprimir nota

Comprar este artículo
Otros artículos escogidos

Referencias bibliográficas
1. Marsden PD. Mucosal leishmaniasis ("espundia" Escomel, 1911). Trans R Soc Trop Med Hyg 80:859-876, 1986.

2. Lucas CM, Franke ED, Cachay MI, Tejada A, Cruz ME, Kreutzer RD, Barker DC, McCann SHE, Watts D. Geographic distribution and clinical description of leishmaniasis cases in Peru. Am J Trope Med Hyg 59:312-317, 1998.

3. Guthmann JP, Arlt D, García LM, Rosales M, De Jesús Sánchez J, Alvarez E, Lonlas S, Conte M, Bertoletti G, Fournier C, Huari R, Torreele E, Llanos Cuentas A. Control of mucocutaneous leishmaniasis, a neglected disease: results of a control programme in Satipo Province, Peru. Trop Med Int Health 10:856-862, 2005.

4. Miranda Verastegui C, Llanos Cuentas A, Arevalo I, Ward BJ, Matlashewski G. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin Infect Dis 40:1395-1403, 2005.

5. Berman J. Clinical status of agents being developed for leishmaniasis. Expert Opin Investig Drugs 14:1337-1346, 2005.

6. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 24:684-703, 1997.

7. Croft SL. Monitoring drug resistance in leishmaniasis. Trop Med Intern Health 6:899-905, 2001.

8. Llanos Cuentas A, Echevarría J, Cruz M, La Rosa A, Campos P, Campos M, Franke E, Berman J, Modabber F, Marr J. Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of micosal leishmaniasis. Clin Infect Dis 25:677-84, 1997.

9. Franke ED, Wignall FS, Cruz ME, Rosales E, Tovar AA, Lucas CM, Llanos Cuentas A, Berman JD. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann Intern Med 113:934-940, 1990.

10. Franke ED, Llanos Cuentas A, Echevarría J, Cruz ME, Campos P, Tovar AA, Lucas CM, Berman JD. Efficacy of 2-day and 4-day regimens of sodium stibogluconate (pentostam) in the treatment of mucosal leishmaniasis. Am J Trop Med Hyg 51:77-82, 1994.

11. Marsden PD, Llanos Cuentas EA, Lago EL, Cuba CC, Barreto AC, Costa JM, Jones TC. Human mucocutaneous leishmaniasis in tres bracos, Bahia-Brazil. An area of Leishmania braziliensis braziliensis transmission. III. Mucosal disease presentation and initial evolution. Rev Soc Bras Med Trop 17:179-186, 1994.

12. Harbath S, Burke J, Lloyd J, Evans R, Pestotnik S, Samore M. Clinical and economical outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis 35:120-127, 2002.

13. Andersen EM, Cruz Saldarriaga ME, Llanos Cuentas A, Cjuno ML, Echevarría J, Miranda Verastegui C, Colina O, Berman JD. Comparison of meglumine antimoniate and pentamydine for Peruvian cutaneous leishmaniasis. Am J Trop Med Hyg 72:133-137, 2005.

14. Vélez I, Agudelo S, Hendricks E, Puerta J, Grogl M, Modabber F, Berman J. Inefficacy of allopurinol for Colombian cutaneous leishmaniasis: a randomized, controlled trial. Ann Intern Med 126:232-236, 1997.

15. Navin TR, Arana BA, Arana FE, Berman JD, Chajon JF. Placebo-controlled clinical trial of sodium stibogluconate (pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 165:528-534, 1992.

16. Mattock NM, Peters W. The experimental chemotherapy of leishmaniasis II. The activity in tissue culture of some antiparasitic and antimicrobial compounds in clinical use. Annals of Tropical Medicine and Parsitology 69:359-371, 1975.

17. Teklemariam S, Hiwot AG, Frommel D, Miko TL, Ganlov G, Brycesson A. Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica. Trans R Soc Trop Med Hyg 88:334-339, 1994.

18. El-On J, Halevy S, Grunwald MH, Weinrauch L. Topical treatment of old world cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J Am Acad Dermatol 27:227-231, 1992.

19. Soto J, Toledo JT, Gutiérrez P, Arboleda M, Nicholls RS, Padilla JR, Berman JD, English CK, Grogl M. Treatment of cutaneous leishmaniasis with a topical anti leishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg 66:147-151, 2002.

20. Soto J, Hernández N, Mejía H, Grogl M, Berman J. Successful treatment of new world cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimoniate. Clin Infect Dis 20:47-51, 1995.

21. Jha TK, Olliaro P, Thakur CPN, Kanyok TP, Singhania BL, Singh IJ, Singh NPK, Akhourny S, Jha S. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 316:1200-1205, 1998.

22. Thakur CP, Kanvok TP, Pandey AK, Sinha GP, Messick C, Olliaro P. Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. Trans R Soc Trop Med Hyg 94:432-433, 2000.

23. Romero GAS, Lessa HA, Orge MGO, Macedo VO, Marsden PD. Mucosal leishmaniasis treatment with aminosidine sulphate: results of two-year follow-up. Rev Soc Bras Med Trop 31:511-516, 1998.

24. López M, Inga R, Cangalaya M, Echevarría J, Llanos Cuents A, Arévalo J. Diagnosis of Leishmania using the polymerase chain reaction: a simplified procedure for field work. Am J Trop Med Hyg 49:348-356, 1993.

25. Soto J, Grogl M, Berman J, Olliaro P. Limited efficacy of injectable aminosidine as single-agent therapy for Colombian cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 88:695-698, 1994.

26. Hepburn NC, Tidman MJ, Hunter JAA. Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis. Trans R Soc Top Med Hyg 88:700-703, 1994.

27. Neal RA, Allen S, McCoy N, Olliaro P, Croft Sl. The sensitivity of Leishmania species to aminosidine. J Antimicrob Chemother 35:677-584, 1995.

28. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 19:111-126, 2006.

29. Thakur CP, Kanvok TP, Pandey AK, Sinha GP, Zaniewski AE, Houlihan HH, Olliaro P. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 94:429-31, 2006.

30. Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 5:763-774, 2005.

Otros artículos de Alejandro Llanos-Cuentas

Arevalo I, Tulliano G, Quispe A, Spaeth G, Matlashewski G, Llanos Cuentas A, Pollack H. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis 44(12):1549-54, 2007.

Boggild AK, Miranda Verastegui C, Espinosa D, Arévalo J, Adaui V, Tulliano G, Llanos Cuentas A, Low DE. Evaluation of a microculture method for the isolation of Leishmania parasites from cutaneous lesions in Peru. J Clin Microbiol 2007.

Arévalo J, Ramírez L, Adaui V, Zimic M, Tulliano G, Miranda Verastegui C, Lazo M, Loayza Muro R, De Doncker S, Maurer A, Chappuis F, Dujardin JC, Llanos Cuentas A. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. J Infect Dis 195(12):1846-51, 2007.

Bharti AR, Patra KP, Chuquiyauri R, Kosek M, Gilman RH, Llanos Cuentas A, Vinetz JM. Polymerase chain reaction detection of Plasmodium vivax and Plasmodium falciparum DNA from stored serum samples: implications for retrospective diagnosis of malaria. Am J Trop Med Hyg 77(3):444-6, 2007.

Nolder D, Roncal N, Davies CR, Llanos Cuentas A, Miles MA. Multiple hybrid genotypes of Leishmania (viannia) in a focus of mucocutaneous Leishmaniasis. Am J Trop Med Hyg 76(3):573-8, 2007.


Para comunicarse con Alejandro Llanos-Cuentas mencionar a SIIC como referencia:

---

Acerca del trabajo completo

LA AMINOSODINA NO ES EFECTIVA PARA LA LEISHMANIASIS MUCOCUTANEA

Título original en castellano
Aminosidina parenteral no es efectiva para leishmaniasis mucocutanea en Peru

Autores
Alejandro Llanos-Cuentas¹, Juan Echevarria², Carlos Seas³
1 Médico, Instituto de Medicina Tropical Alexander Von Humboldt, Universidad Peruana Cayetan, Lima, Perú, Investigador
2 Médico, Instituto de Medicina Tropical Alexander Von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Perú, Investigador
3 Médico, Instituto de Medicina Tropical Alexander Von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Perú, Investigador

Acceso a la fuente original
The American Journal of Tropical Medicine and Hygiene
http://www.ajtmh.org/

El artículo se relaciona estrictamente con las especialidades de siicsalud
El artículo se conecta secundariamente con las especialidades